featured
FDA Approved Tucatinib for HER2-Positive Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
- Tukysa Prescribing Information. Tukysa U.S. Product Information. Last updated: April 2020. Bothell, WA: Seattle Genetics, Inc.
- National Comprehensive Cancer Network. Breast Cancer (Version 3.2020). Last update: March 6, 2020.
- Murthy RK, Loi S, Okines A, et al. Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer [published correction appears in N Engl J Med. 2020 Feb 6;382(6):586]. N Engl J Med. 2020;382(7):597–609.
Disclosure statements are available on the authors' profiles: